Its applicability is demonstrated in the primary tauopathy Progressive Supranuclear Palsy by extracting mechanistic information from the distribution of tau aggregates at different disease stages from post‐mortem human brain. This evidence concerns the gene MAPT and progressive supranuclear palsy.